Living on three time scales: The dynamics of plasma cell and antibody populations illustrated for hepatitis a virus

PLoS Computational Biology

Volumn 8, Issue 3, 2012, Pages

  Andraud, Mathieu ^a   Lejeune, Olivier ^a,b   Musoro, Jammbe Z ^c,d   Ogunjimi, Benson ^a   Beutels, Philippe ^a   Hens, Niel ^a,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c HASSELT UNIVERSITY   (Belgium)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CLINICAL RESEARCH; CYTOLOGY; DISEASES; ESTIMATION; IMMUNOLOGY; KINETICS; VACCINES; VIRUSES;

BONE MARROW; DEVELOPMENT POLICIES; HEALTH POLICY; HEPATITIS A VIRUS; HUMORAL IMMUNITY; INDIVIDUAL PREDICTION; NATURAL INFECTION; PLASMA CELLS; THREE TIME-SCALES; VACCINE DEVELOPMENT;

ANTIBODIES;

HEPATITIS A VACCINE;

ADULT; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD SAMPLING; CELL INTERACTION; CELL SUBPOPULATION; CELL SURVIVAL; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NONHUMAN; PLASMA CELL; PREDICTION;

HEPATITIS A VIRUS;

EID: 84861133618     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002418     Document Type: Article

References (36)

1. Siegriest CA, (2008) Vaccine Immunology. Vaccines Oxford, U.K. Elsevier pp. 17-36.
2. Amanna IJ, Slifka MK, (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236: 125-138.
3. Waldmann TA, Strober W, (1969) Metabolism of immunoglobulins. Prog Allergy 13: 1-110.
4. Guyton A, Hall J, (2000) Textbook of medical physiology Philadelphia, U.S. W. B. Saunders Company.
5. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of Humoral Immunity to Common Viral and Vaccine Antigens. N Engl J Med 357: 1903-1915.
6. Bernasconi NL, Traggiai E, Lanzavecchia A, (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298: 2199-2202.
7. Genova GD, Roddick J, McNicholl F, Stevenson FK, (2006) Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood 107: 2806-2813.
8. Liu YJ, Grouard G, deBouteiller O, Banchereau J, (1996) Follicular dendritic cells and germinal centers. International Review of Cytology- a Survey of Cell Biology, Vol 166 San Diego Academic Press Inc pp. 139-179.
9. Tew JG, Kosco MH, Burton GF, Szakal AK, (1990) Follicular Dentritic Cells As Accessory Cells. Immunol Rev 117: 185-211.
10. Leyendeckers H, Odendahl M, Lohndorf A, Irsch J, Spangfort M, et al. (1999) Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 29: 1406-1417.
11. Lanzavecchia A, Sallusto F, (2009) Human B cell memory. Curr Opin Immunol 21: 298-304.
12. Manz RA, Hauser AE, Hiepe F, Radbruch A, (2005) Maintenance of serum antibody levels. Annu Rev Immunol 23: 367-386.
13. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, et al. (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6: 741-750.
14. Slifka M, Matloubian M, Ahmed R, (1995) Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 69: 1895-1902.
15. Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, et al. (2001) Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults*. J Med Virol 65: 6-13.
16. Van Herck K, Beutels P, Van Damme P, Beutels M, Van den Dries J, et al. (2000) Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60: 1-7.
17. Van Herck K, Van Damme P, (2001) Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. J Med Virol 63: 1-7.
18. Wiedermann G, Kundi M, Ambrosch F, (1998) Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop 69: 121-125.
19. Wiens BL, Bohidar NR, Pigeon JG, Egan J, Hurni W, et al. (1996) Duration of protection from clinical hepatitis A disease after vaccination with VAQTA®. J Med Virol 49: 235-241.
20. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, et al. (2007) Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25: 4324-4333.
21. David M-P, Van Herck K, Hardt K, Tibaldi F, Dubin G, et al. (2009) Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 115: S1-S6.
22. Van Damme P, Matheï C, Thoelen S, Meheus A, Safary A, et al. (1994) Single dose inactivated hepatitis A vaccine: Rationale and clinical assessment of the safety and immunogenicity. J Med Virol 44: 435-441.
23. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, et al. (1994) Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44: 446-451.
24. Andre FE, Hepburn A, D'Hondt E, (1990) Inactivated candidate vaccines for hepatitis A. Prog Med Virol 37: 72-95.
25. Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, et al. (2010) A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87: 706-713.
26. Lavielle M, Mentre F, (2007) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34: 229-249.
27. Efron B, Tibshirani J, (1993) An introduction to the bootstrap New York Chapman & Hall, Inc.
28. Gesemann M, Scheiermann N, (1995) Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13: 443-447.
29. Honorati MC, Palareti A, Dolzani P, Busachi CA, Rizzoli R, et al. (1999) A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Clin Exp Immunol 116: 121-126.
30. Teunis PF, van der Heijden OG, de Melker HE, Schellekens JF, Versteegh FG, et al. (2002) Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 129: 479-489.
31. Karlsson MO, Savic RM, (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82: 17-20.
32. Stram DO, Lee JW, (1994) Variance-components testing in the longitudinal mixed effects model. Biometrics 50: 1171-1177.
33. Molenberghs G, Verbeke G, (2005) Models for Discrete Longitudinal Data New-York Springer.
34. Delem A, Safary A, De Namur F, Hauser P, D'Hondt E, (1993) Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A. Vaccine 11: 479-484.
35. Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet 362: 1065-1071.
36. Van Damme P, Van Herck K, (2007) A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5: 79-84.